<p>Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy

Published:2020-06 Issue: Volume:Volume 10 Page:29-38
ISSN:1179-9900
Container-title:Degenerative Neurological and Neuromuscular Disease
language:en
Short-container-title:DNND

Author:

Goldschmidt Carolyn H^ORCID,Hua Le H^ORCID

Publisher

Informa UK Limited

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference50 articles.

1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB multiple sclerosis study group. Neurology. 1993;43(4):655–661. doi:10.1212/WNL.43.4.655

3. Long-term use of interferon-β in multiple sclerosis increases Vδ1−Vδ2−Vγ9− γδ T cells that are associated with a better outcome

4. Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring blood transcriptomic signatures in patients with herpes zoster and postherpetic neuralgia;Frontiers in Cellular and Infection Microbiology;2024-08-15

2. Neurological Impact of Type I Interferon Dysregulation;Rare Neurodegenerative Disorders - New Insights [Working Title];2024-07-31

3. Article Review: Multiple Sclerosis;Journal for Research in Applied Sciences and Biotechnology;2024-03-07

4. Berberine: A natural modulator of immune cells in multiple sclerosis;Immunity, Inflammation and Disease;2024-03

5. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3